Velaglucerase alfa
- Generic Name
- Velaglucerase alfa
- Brand Names
- Vpriv
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 884604-91-5
- Unique Ingredient Identifier
- 23HYE36B0I
- Background
Velaglucerase alfa is a gene-activated human recombinant glucocerebrosidase used for the treatment of Type 1 Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase. Additionally, Velaglucerase alfa has also been investigated for use in Type 3 Gaucher disease.
- Indication
Velaglucerase alfa is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy for pediatric and adult patients with type 1 Gaucher disease.
- Associated Conditions
- Gaucher Disease, Type 1
- Associated Therapies
- -
A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease
- First Posted Date
- 2022-09-07
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 20
- Registration Number
- NCT05529992
- Locations
- 🇨🇳
Lanzhou University Second Hospital, Lanzhou, Gansu, China
🇨🇳The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳Beijing Children's Hospital, Capital Medical University, Beijing, Beijing, China
Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in Treatment-naïve Participants With Type 1 Gaucher Disease
- Conditions
- Interventions
- First Posted Date
- 2015-10-12
- Last Posted Date
- 2022-02-01
- Lead Sponsor
- Shire
- Target Recruit Count
- 21
- Registration Number
- NCT02574286
- Locations
- 🇮🇱
Rabin Medical Center, Petah Tikva, Israel
🇪🇸Hospital Quironsalud Zaragoza, Zaragoza, Spain
🇮🇱Rambam Health Care Campus, Haifa, Israel
The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease
- Conditions
- Interventions
- First Posted Date
- 2015-08-19
- Last Posted Date
- 2018-03-02
- Lead Sponsor
- Baylor Research Institute
- Registration Number
- NCT02528617
- Locations
- 🇺🇸
Baylor Research Institute, Dallas, Texas, United States
Multicenter Extension Study of Velaglucerase Alfa in Japanese Patients With Gaucher Disease
- First Posted Date
- 2013-04-30
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Shire
- Target Recruit Count
- 5
- Registration Number
- NCT01842841
- Locations
- 🇯🇵
Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
🇯🇵The Jikei University School of Medicine, Minato-ku, Tokyo, Japan
🇯🇵Chiba Children's Hospital, Chiba, Japan
Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease
- Conditions
- First Posted Date
- 2009-08-07
- Last Posted Date
- 2021-05-21
- Lead Sponsor
- Shire
- Registration Number
- NCT00954460
- Locations
- 🇺🇸
Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸North Shore Hematology/Oncology - Manhasset, Manhasset, New York, United States
Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A (ERT)
- First Posted Date
- 2006-10-24
- Last Posted Date
- 2021-06-22
- Lead Sponsor
- Shire
- Target Recruit Count
- 10
- Registration Number
- NCT00391625
- Locations
- 🇮🇱
Shaare Zedek Medical Center, Jerusalem, Israel
🇷🇴Maria Sklodowska Curie Children's Hospital, Bucharest, Romania
🇷🇸Mother and Child Health Care Institute of Serbia, Belgrade, Serbia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.